Document:

Exhibit
10.1

SETTLEMENT
AND RELEASE AGREEMENT

 

This
Settlement and Release Agreement (the "Agreement") is entered into by and between CHEMDIV, INC. ("Chemdiv"), REGEN
BIOPHARMA, INC. ("Regen"), ZANDER THERAPEUTICS, INC., and DAVID KOOS ("Koos"). Regen, Zander, and Koos may sometimes
be collectively referred to herein as "Defendants." Chemdiv and Defendants are sometimes collectively referred to herein as
the "Parties."

RECITALS

A. WHEREAS,
Chemdiv provided certain services to Regen and/or Zander from approximately 2016 through 2019;

B. WHEREAS,
a dispute arose between the Parties with respect to Defendants' alleged failure to pay for services rendered by Chemdiv;

C. WHEREAS,
on or around December 13, 2019, Chemdiv caused a complaint to be filed against Defendants in the Superior Court of California, County
of San Diego - Central District, Case No. 37-2019-00066495-CU-BC-CTL, alleging breach of contract, unfair business practices under California
Business & Professions Code §§17200, et seq., fraud, bad faither denial of a contract, and declaratory relief (the "Litigation"),
all of which Defendants deny; and

D. WHEREAS,
the Parties desire to resolve and conclude all matters between them, known and unknown, including but not limited to those which were
or could have been raised in the Litigation or which otherwise arise out of or relate to the business relationship between Chemdiv and
Defendants. 

    	1 

    	 

    

AGREEMENT

The
Parties hereby agree as follows: 

1. Payment
by Regen to Chemdiv- Contingent on the Happening of Events. As an express requirement for Regen to make the payment to Chemdiv set forth
herein, Regen must file certain documents with the SEC in order to maintain is "listed" status. Such documents must be filed
by Regen in acceptable form on or before September 24, 2021, and Regen intends to file all required documents by this date. Assuming
such documents are filed by Regen in an acceptable format by September 24, 2021, as determined in Regen's sole and absolute discretion,
Regen shall make payment to Chemdiv in the lump sum, gross amount of Eight Hundred Thousand Dollars and No Cents ($800,000.00). Chemdiv
shall be responsible for any and all tax payments, tax filings, and tax implications it may be required to pay, file, or address as a
result of the payment set forth herein. Regen shall confirm in writing on or before close of business on September 24, 2021 whether or
not the requisite documents have been prepared and filed and whether the contingency set forth herein has been met, through an email
from Koos's counsel to Chemdiv's counsel. Assuming such contingency has been met, as confirmed by Regen in writing, Regen shall make
the settlement payment to Chemdiv by no later than September 30, 2021. Payment shall be made by wire to an account designated by Chemdiv,
or as otherwise directed by Chemdiv in writing. If Payment is not made by September 30, 2021, then this Agreement is void and shall have
no effect unless the deadline to pay is extended in writing by all parties to this Agreement. The releases provided for in this Agreement
shall also be void and shall have no effect.

2.
 Chemdiv to Provide Documents and Information to Regen upon Payment. Upon payment of the amount
set forth in paragraph 1 by Regen to Chemdiv, Chemdiv shall provide Regen with all results, compounds identified, and data generated
by Chemdiv relative to its NR2F6 research conducted on behalf of or at the direction of Regen and/or Zander, together with specification
of the means of conducting such research, including but not limited to protocols used in conducting such research. Ownership rights relating
to the intellectual property reflected in such data, information, and documents shall become the property of Regen and Zander.

3.
 Temporary Stay of Case Pending Fulfillment of Contingency. Upon full execution of this Agreement,
the Parties agree to stay the pending Litigation to allow for the contingency set forth in paragraph 1 to be fulfilled (or alternatively,
for written confirmation that such contingency has not been fulfilled) by September 24, 2021. Scheduled depositions shall be stayed and
the Parties agree that, to the extent deemed necessary, the Parties shall jointly apply to the Court handling the Litigation to continue
the trial in this matter, currently set for October 29, 2021, together with all related dates and deadlines including those related to
discovery, to the Court's next available date (but in no event earlier than December 10, 2021, to allow the Parties adequate time to
complete all necessary depositions, expert exchanges and expert depositions, and other such discovery and trial preparation work as may
be necessary should the contingency set forth in paragraph 1 not be met).

4.
 Dismissal of the Litigation with Prejudice. Upon Chemdiv’s receipt of the Eight Hundred
Thousand Dollars and No Cents ($800,000.00) payment from Regen by no later than September 30, 2021 Chemdivshall cause the Litigation
to be dismissed with prejudice by filing the necessary requests for dismissal and taking all other steps reasonably necessary to accomplish
such dismissal within ten (10) business days of the receipt of the $800,000.

5.
 General Releases of Defendants.

For
good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and as a material inducement to Defendants
to enter into this Agreement, uponexecution of this Agreement and Chemdiv’s receipt of the Eight Hundred Thousand Dollars and No
Cents ($800,000.00) payment from Regen by no later than September 30, 2021and to the greatest extent permitted by law, Chemdiv, on behalf
of itself and its respective successors, assigns, officers, directors, owners, members, investors, agents, attorneys, employees, representatives,
insurers and each of them, fully waives, releases, remits and forever discharges Defendants, and their respective successors, assigns,
officers, directors, owners, members, investors, agents, attorneys, employees, representatives, insurers and each of them, of and from
any and all claims which may exist between them, known and unknown, and specifically including, without limitation, those claims which
were or could have been raised in the Litigation and claims arising from or relating to the business relationship between Chemdiv and
Defendants and including any claims for attorney's fees or costs incurred as a result of or in relation to the Litigation or this Agreement.
The releases set forth herein shall not include any claims concerning a breach of this Agreement. In the eventChemdiv does not receive
the Eight Hundred Thousand Dollars and No Cents ($800,000.00) payment from Regen by no later than September 30, 2021, the releases set
forth herein shall be of no force or effect and the Litigation shall continue.

6.
 General Release of Chemdiv.

For
good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and as a material inducement to Chemdiv to
enter into this Agreement, upon execution of this Agreement and Chemdiv’s receipt of the Eight Hundred Thousand Dollars and No
Cents ($800,000.00) payment from Regen by no later than September 30, , and to the greatest extent permitted by law, Defendants, on behalf
of themselves and their respective successors, assigns, officers, directors, owners, members, investors, agents, attorneys, employees,
representatives, insurers and each of them, fully waive, release, remit and forever discharge Chemdiv, and its respective successors,
assigns, officers, directors, owners, members, investors, agents, attorneys, employees, representatives, insurers and each of them, of
and from any and all claims which may exist between them, known and unknown, and specifically including, without limitation, those claims
which were or could have been raised in the Litigation and claims arising from or relating to the business relationship between Chemdiv
and Defendants and including any claims for attorney's fees or costs incurred as a result of or in relation to the Litigation or this
Agreement. The releases set forth herein shall not include any claims concerning a breach of this Agreement. In the event that Chemdiv
does not receive the Eight Hundred Thousand Dollars and No Cents ($800,000.00) payment from Regen by no later than September 30, 20211,
the releases set forth herein shall be of no force or effect and the Litigation shall continue.

7. Release
of Unknown Claims.

Chemdiv
and Defendants intend this Agreement to waive and release all known and unknown claims between them to the greatest extent permitted
by law. To that end, Chemdiv and Defendants specifically acknowledge and waive the benefits of the provisions of Section 1542 of the
Civil Code of the State of California, which provides as follows:

"A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR
AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE
DEBTOR OR RELEASED PARTY."

8. Miscellaneous
Provisions.

a. This
Agreement is the product of arms-length negotiations and is considered to be jointly drafted. As such, it shall not be construed against
any party because that party caused it to be reduced to a written instrument. The headings used herein are for reference only and shall
not affect the construction of this Agreement. This Agreement may be executed and delivered in two or more counterparts, each of which
when so executed and delivered shall be the original, but such counterparts together shall constitute but one and the same instrument.

b. This
Agreement, and all the terms and provisions contained herein, shall bind the heirs, personal representatives, successors and assigns
of each party, and inure to the benefit of each party, its agents, directors, officers, employees, servants, successors, and assigns.
By their respective signatures below, each of the Parties warrants and represents that it has not made, and will not make, any assignment,
conveyance, or transfer of any kind or nature of any claim, chose in action, right of action, or any right of any kind whatsoever, embodied
in any of the claims that are released herein, and that no other person or entity of any kind had or has any interest in any of the claims
released herein. By signing below, each of the Parties warrants and represents that, other than the Litigation, no other claims, lawsuits,
or complaints arising from or relating to the claims being released herein have been filed or will be filed by the Parties. 

c. This
Agreement shall be construed as a whole in accordance with its fair meaning and in accordance with the internal laws of the State of
California without regard to its conflict of laws provisions or those of any other state, territory, or country. The Parties agree to
submit any dispute between them arising from or relating to this Agreement, the payments or other obligations set forth herein, the claims
waived herein, or the business relationship between Chemdiv and Defendants, to the sole and exclusive jurisdiction of the state courts
of the State of California, and agree to submit themselves to the sole and exclusive jurisdiction of the state courts of the State of
California with respect to such claims. To the greatest extent permitted by law, any lawsuit filed arising from or relating in any way
to this Agreement, the payments or other obligations set forth herein, the claims waived herein, or the business relationship between
Chemdiv and Defendants shall be filed and heard solely in the County of San Diego.

d. This
Agreement embodies the entire agreement of all the Parties hereto who have executed it and supersedes any and all other agreements, understandings,
negotiations, or discussions, either oral or in writing, express or implied, between the Parties to this Agreement. This is a fully-integrated
agreement. The Parties to this Agreement each acknowledge that no representations, inducements, promises, agreements or warranties, oral
or otherwise, have been made by them, or anyone acting on their behalf, which are not embodied and expressly set forth in this Agreement;
that they have not executed this Agreement in reliance on any representation, inducement, promise, agreements, warranty, fact or circumstances
not expressly set forth in this Agreement; and that no representation, inducement, promise, agreement or warranty not contained in this
Agreement, including but not limited to any purported settlements, modifications, waivers, or terminations of this Agreement, shall be
valid or binding, unless executed in writing by all of the Parties to this Agreement. This Agreement may be amended, and any provision
herein waived, but only in writing, signed by the party against whom such an amendment or waiver is sought to be enforced.

e. It
is understood and agreed by the Parties that this Agreement represents a compromise and settlement of various matters and that the terms
of this Agreement shall not be construed to be an admission of any liability or obligation by any Party to another other Party or any
other person.

f. The
Parties shall execute and deliver any and all additional papers, documents and other assurances and shall do any and all acts and things
reasonably necessary in connection with the performance of their respective obligations hereunder and to carry out the intent of the
Parties hereto.

g. The
Parties agree to bear their own costs and fees, including attorney fees. In any action or proceeding brought to enforce any provision
of this Agreement or where any provision hereof is validly asserted as a defense, the successful party in such action or proceeding shall
be entitled to recover its reasonable attorney's fees and costs from the non-prevailing party or parties, in addition to any other available
remedy.

h. Each
individual signing below on behalf of a business entity warrants and represents that he or she does so with full authority to execute
this Agreement on behalf of such entity and to bind such entity to the terms and conditions set forth herein, and that such signature
may be relied upon by all other Parties hereto.

    	2 

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Settlement and Release Agreement on the dates shown below.

 

	 	 	CHEMDIV, INC.
	 	 	 
	Dated: 09/15/2021	 	/s/ Ronald M. Demuth
	 	 	By: Ronald M. Demuth
	 	 	Its: Assistant Corporate Secretary
	 	 	 
	 	 	 
	 	 	REGEN BIOPHARMA, INC.
	 	 	 
	Dated: 09/12/2021	 	/s/ David Koos
	 	 	By: /s/ David Koos
	 	 	Its: CEO
	 	 	 
	 	 	 
	 	 	ZANDER THERAPEUTICS, INC.
	 	 	 
	Dated: 09/12/2021	 	/s/ David Koos
	 	 	By: David Koos
	 	 	Its: CEO
	 	 	 
	 	 	 
	Dated: 09/12/2021	 	/s/ David Koos
	 	 	By: DAVID KOOS, an individual

    	3cruc_ex101.htm

EXHIBIT 10.1
  
 MUTUAL TERMINATION AGREEMENT
  
 This Mutual Termination Agreement (the “Termination Agreement”) is made and entered into this September 2, 2021 is between CRUCIAL INNOVATIONS CORP., a Nevada Corporation (“CINV”) and MERCANTILE GLOBAL HOLDINGS, INC., a Delaware Corporation (“MGH”). CINV and MGH may be referred individually as a “Party” and collectively as the “Parties”.
  
 RECITALS
  
 WHEREAS, the Parties entered into that certain Equity Purchase Agreement dated December 31, 2020 (the “Equity Purchase Agreement”) pursuant to which CINV would acquire from MGH 100% of the shares of Mercantile Bank International Corp. in exchange of $500,000 and the issuance to MGH of an amount of CINV shares that would equal 85% of the ownership interest in CINV.
  
 WHEREAS, the Parties now desire to terminate the Equity Purchase Agreement.
  
 NOW, THEREFORE, in consideration of the covenants and agreements set forth in this Termination Agreement, the Parties agree as follows:
  
 	 1.
	 Mutual Termination of Equity Purchase Agreement. Effective immediately, the Parties hereby abandon the transactions contemplated by the Equity Purchase Agreement and mutually terminate the Equity Purchase Agreement.

	  
	  

	 2.
	 Release of Claims.

    
 	  
	 2.1.
	  CINV Release. Effective immediately, CINV and each of its predecessors, successors, subsidiaries, affiliates, and assigns (and any of the present and former officers, directors, and employees of each of the foregoing) (each, a “CINV Releasing Party”), in their capacity as such, hereby covenants not to sue and forever releases and discharges MGH (and each of its present and former shareholders, directors, officers, representatives, advisors (including but not limited to financial advisors), attorneys, accountants, employees, agents, parents, subsidiaries, affiliated persons and entities, predecessors, successors and assigns and heirs, executors and administrators and all persons acting in concert with any such party) (each, a “MGH Released Party”) from all manner of claims, actions, causes of action or suits, at law or in equity, known or unknown, which each now has or hereafter can, shall or may have by reason of any matter, cause or thing whatsoever relating to or arising out of the this Termination Agreement, Equity Purchase Agreement, or the agreements or instruments ancillary thereto or the transactions contemplated thereby, or any action or failure to act under the Equity Purchase Agreement or in connection therewith, or in connection with the events leading to the abandonment of the transactions contemplated in the Equity Purchase Agreement and the mutual termination of the Equity Purchase Agreement, excepting only any claim, action, cause of action or suit arising (i) out of an undertaking or promise contained in this Termination Agreement, or (ii) with respect to any statements made or actions taken after the date of this Termination Agreement.

    
 	 
	1
	

	 

  
 	  
	 2.2. 
	 MGH Release. Effective immediately, MGH and each of its predecessors, successors, subsidiaries, affiliates, and assigns (and any of the present and former officers, directors, and employees of each of the foregoing) (each, a “MGH Releasing Party”), in their capacity as such, hereby covenants not to sue and forever releases and discharges CINV (and each of its present and former shareholders, directors, officers, representatives, advisors (including but not limited to financial advisors), attorneys, accountants, employees, agents, parents, subsidiaries, affiliated persons and entities, predecessors, successors and assigns and heirs, executors and administrators and all persons acting in concert with any such party) (each, a “CINV Released Party”) from all manner of claims, actions, causes of action or suits, at law or in equity, known or unknown, which each now has or hereafter can, shall or may have by reason of any matter, cause or thing whatsoever relating to or arising out of the this Termination Agreement, Equity Purchase Agreement, or the agreements or instruments ancillary thereto or the transactions contemplated thereby, or any action or failure to act under the Equity Purchase Agreement or in connection therewith, or in connection with the events leading to the abandonment of the transactions contemplated in the Equity Purchase Agreement and the mutual termination of the Equity Purchase Agreement, excepting only any claim, action, cause of action or suit arising (i) out of an undertaking or promise contained in this Termination Agreement, or (ii) with respect to any statements made or actions taken after the date of this Termination Agreement.

   
 	 3.
	 Publicity/SEC Filings. The Parties shall not make any public statement or press release regarding this Termination Agreement unless MGH consents in writing to such public statement or press release. However, CINV is authorized to disclose and file a copy of this Termination Agreement as part of any applicable and legally required filings, subject to MGH’s prior review and written approval (which shall not be unreasonably withheld) with the Securities Exchange Commission.

	  
	  

	 4.
	 Representations and Warranties.

    
 	  
	 4.1.
	  CINV represents to MGH that CINV has all requisite corporate power and authority to enter into this Termination Agreement and to take the actions contemplated hereby. The execution and delivery of this Termination Agreement and the actions contemplated hereby have been duly authorized by all necessary corporate action on the part of the CINV. This Termination Agreement has been duly executed and delivered by CINV and constitutes a valid and binding agreement of CINV, enforceable against it accordance with its terms.

	  
	  
	  

	  
	 4.2. 
	 MGH represents to CINV that MGH has all requisite organizational power and authority to enter into this Termination Agreement and to take the actions contemplated hereby. The execution and delivery of this Termination Agreement and the actions contemplated hereby have been duly authorized by all necessary action on the part of MGH. This Termination Agreement has been duly executed and delivered by MGH and constitutes a valid and binding agreement of MGH, enforceable against it in accordance with its terms.

   
 	 
	2
	

	 

    
 	 5.
	 General Provisions.

    
 	  
	 5.1.
	 Entire Agreement; Assignment. This Termination Agreement (including the documents and instruments referred to herein) constitutes the entire agreement between the Parties in respect of the subject matter hereof and supersedes all other prior agreements and understandings, both written and oral, between the Parties in respect of the subject matter hereof. Neither this Termination Agreement nor any of the rights, interests or obligations hereunder shall be assigned by operation of law (including by merger or consolidation) or otherwise without the prior written consent of the other Parties. Any assignment in violation of the preceding sentence shall be null and void.

	  
	  
	  

	  
	 5.2.
	 Notices. All notices, requests, instructions or other documents to be given under this Termination Agreement shall be in writing and shall be deemed given (i) three business days following sending by registered or certified mail, postage prepaid, (ii) when sent if sent by email; (iii) when delivered, if delivered personally to the intended recipient, and (iv) one business day following sending by overnight delivery via a national courier service, and in each case, addressed to a Party at the address set forth in the signature page of this Termination Agreement.

	  
	  
	  

	  
	 5.3. 
	 Governing Law. This Termination Agreement shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to the choice of law principles thereof.

	  
	  
	  

	  
	 5.4.
	 Headings. The headings of the various sections of this Termination Agreement have been inserted for convenience of reference only and shall not be deemed to be part of this Termination Agreement.

	  
	  
	  

	  
	 5.5. 
	 Parties in Interest. This Termination Agreement shall be binding upon and inure solely to the benefit of each Party and its successors and permitted assigns, and nothing in this Termination Agreement, express or implied, is intended to or shall confer upon any other person any rights, benefits or remedies of any nature whatsoever under or by reason of this Termination Agreement.

	  
	  
	  

	  
	 5.6. 
	 Severability. The provisions of this Termination Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Termination Agreement, or the application thereof to any person or any circumstance, is invalid or unenforceable, (i) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (ii) the remainder of this Termination Agreement and the application of such provision to other persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction.

  
 	 
	3
	

	 

  
 	  
	 5.7.
	 Counterparts. This Termination Agreement may be executed in two or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Parties. The Parties agree that delivery of executed signature pages by electronic mediums shall be sufficient to render this Termination Agreement effective.

	  
	  
	  

	  
	 5.8. 
	 Cooperation. The Parties shall cooperate and promptly prepare and file all necessary documentation to withdraw all applications, notices, petitions, and filings made with, and shall use their reasonable best efforts to terminate the proceedings before, any governmental authority in connection with the Equity Purchase Agreement.

	  
	  
	  

	  
	 5.9.
	 Amendment and Modification. This Termination Agreement may be amended, modified, and supplemented only by a written document executed by the Parties which specifically states that it is an amendment, modification, or supplement to this Termination Agreement.

    	 CRUCIAL INNOVATIONS CORP.
	  
	 MERCANTILE GLOBAL HOLDINGS INC.
	  

	  
	  
	  
	  

	 By: 
	 
	  
	 By: 
	  
	  

	 Name: 
	 Laura De Leon Castro
	  
	 Name: 
	 J. Robert Collins, Jr.
	  

	 Title: 
	 Chief Executive Officer
	  
	 Title: 
	 Chief Executive Officer
	  

   
 	 
	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]